NOMDEDEU GUINOT, JOSEP FRANCESC FGS
jnomdedeu@santpau.cat
Blanco , Maria Laura FGS
Brell Martinez, Albert FGS
Bussaglia Petrillo, Elena Mart FGS
Carricondo Morcillo, Maite FGS
Castellet Farrus, Helena IR
Espadaler Pare, Montserrat FGS
Fernandez Rosales, Maria Nieves FGS
Fuentes Hernandez, Francisca FGS
Martinez Sanchez, Elisabeth FGS
Martinez Valverde, Clara Maria FGS
Ortin Quilez, Rosa FGS
Pratcorona Canela, Marta FGS
Remacha Sevilla, Angel Francisco FGS
Sanchez Garcia, Jana FGS
Serra Ferrer, Marta FGS
Ubeda Rodenas, Jose FGS
Baroni M.L., Sanchez Martinez D., Gutierrez Aguera F., Roca Ho H., Castella M., Zanetti S., Velasco Hernandez T., Diaz de la Guardia R., Castano J., Anguita E., Vives S., Nomdedeu J., Lapillone H., Bras A.E., van der Velden V.H.J., Junca J., Marin P., Bataller A., Esteve J., Vick B., Jeremias I., Lopez A., Sorigue M., Bueno C., Menendez P. (2020) 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J IMMUNOTHER CANCER, 8 (1), -. IF: 13,7510
Bataller A., Onate G., Diaz-Beya M., Guijarro F., Garrido A., Vives S., Tormo M., Arnan M., Salamero O., Sampol A., Coll R., Vall-Llovera F., Oliver-Caldes A., Lopez-Guerra M., Pratcorona M., Zamora L., Villamon E., Roue G., Blanco A., Nomdedeu J.F., Colomer D., Brunet S., Sierra J., Esteve J. (2020) Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. BRIT J HAEMATOL, 191 (1), 52-61. IF: 6,9980
Bussaglia E., Pratcorona M., Carricondo M., Sansegundo L., Rubio M.A., Monter A., Brell A., Badell I., Esteve J., Arnan M., Talarn C., Tormo M., Garcia A., Vall-Llovera F., Ortin X., Pedro C., Bargay J., Brunet S., Sierra J., Nomdedeu J. (2020) Application of a digital PCR method for WT1 to myeloid neoplasms in CR and deep ELN WT1 molecular response (< 10 copies). ANN HEMATOL, 99 (4), 765-772. IF: 3,6730
Dohner K., Thiede C., Jahn N., Panina E., Gambietz A., Larson R.A., Prior T.W., Marcucci G., Jones D., Krauter J., Heuser M., Voso M.T., Ottone T., Nomdedeu J.F., Mandrekar S.J., Klisovic R.B., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T., Jansen J.H., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Schlenk R.F., Ganser A., Serve H., Ehninger G., Amadori S., Gathmann I., Benner A., Pallaud C., Stone R.M., Dohner H., Bloomfield C.D. (2020) Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. BLOOD, 135 (5), 371-380. IF: 22,1130
Garcia Erce J.A., Altes A., Lopez Rubio M., Remacha A.F., de la O Abio M., Beneitez D., de la Iglesia S., Dolores de la Maya M., Flores E., Perez G., Pilar Ricard M., Manuel Vagace J. (2020) Management of iron deficiency in various clinical conditions and the role of intravenous iron: Recommendations of the Spanish Erythropathology Group of the Spanish Society of Haematology and Haemotherapy Manejo del déficit de hierro en distintas situaciones clínicas y papel del hierro intravenoso: recomendaciones del Grupo Español de Eritropatología de la SEHH. REV CLIN ESP, 220 (1), 31-42. IF: 1,5560
Mora A., Bosch R., Cuellar-Garcia C., Blanco L., Sierra J., Nomdedeu J., Moreno C. (2020) Gene expression workflow to analyze residual leukemic cells in Chronic Lymphocytic Leukemia. INT J LAB HEMATOL, (), -. IF: 2,8770
Payan-Pernia S., Bernal Noguera S., Rojas Rodriguez E., Serra Ferrer M., Remacha Sevilla A.F. (2020) Mild Thalassemia Intermedia Due to Interaction of δβ-Thalassemia with Triplicated α-Globin Genes. HEMOGLOBIN, (), 294-296. IF: 0,8490
Rio-Machin A., Vulliamy T., Hug N., Walne A., Tawana K., Cardoso S., Ellison A., Pontikos N., Wang J., Tummala H., Al Seraihi A.F.H., Alnajar J., Bewicke-Copley F., Armes H., Barnett M., Bloor A., Bodor C., Bowen D., Fenaux P., Green A., Hallahan A., Hjorth-Hansen H., Hossain U., Killick S., Lawson S., Layton M., Male A.M., Marsh J., Mehta P., Mous R., Nomdedeu J.F., Owen C., Pavlu J., Payne E.M., Protheroe R.E., Preudhomme C., Pujol-Moix N., Renneville A., Russell N., Saggar A., Sciuccati G., Taussig D., Toze C.L., Uyttebroeck A., Vandenberghe P., Schlegelberger B., Ripperger T., Steinemann D., Wu J., Mason J., Page P., Akiki S., Reay K., Cavenagh J.D., Plagnol V., Caceres J.F., Fitzgibbon J., Dokal I. (2020) The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants. NAT COMMUN, 11 (1), -. IF: 14,9190
Voso M.T., Larson R.A., Jones D., Marcucci G., Prior T., Krauter J., Heuser M., Lavorgna S., Nomdedeu J., Geyer S.M., Walker A., Wei A.H., Sierra J., Sanz M.A., Brandwein J.M., de Witte T.M., Jansen J.H., Niederwieser D., Appelbaum F.R., Medeiros B.C., Tallman M.S., Schlenk R.F., Ganser A., Amadori S., Cheng Y., Chen Y., Pallaud C., Du L., Piciocchi A., Ehninger G., Byrd J., Thiede C., Dohner K., Stone R.M., Dohner H., Bloomfield C.D., Lo-Coco F. (2020) Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial. BLOOD ADV, 4 (19), 4945-4954. IF: 6,6860